The Egypt Diabetes Care Devices Market is segmented into Monitoring Devices (Self-monitoring Blood Glucose Device, Continuous Glucose Monitoring Device), Management Devices (Insulin Pump, Insulin Syringes, Cartridges in Reusable pens, Disposable Pens, and Jet Injectors). The report offers the value (in USD million) for the above segments.

Market Snapshot

Egypt Market
Study Period: 2016-2027
Base Year: 2021
CAGR: >3.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Egypt Diabetes Care Devices Market is expected to grow at a CAGR of more than 3.5% during the forecast period (2022-2027). The market is estimated to reach a value of more than USD 430 million by 2027.

The COVID-19 pandemic positively impacted the Egypt diabetes care devices market growth. Patients with diabetes, infected with COVID-19 may experience elevated blood glucose, abnormal glucose variability, and diabetic complications. The prevalence of diabetes in people with COVID-19 caused a significant increase in severity and mortality of COVID-19 in people with either type 1 (T1DM) or type 2 diabetes mellitus (T2DM), especially in association with poor glycemic control. While new-onset hyperglycemia and new-onset diabetes (both T1DM and T2DM) have been increasingly recognized in the context of COVID-19 and have been associated with worse outcomes. To avoid aggravation, a patient's blood glucose should be monitored and managed regularly, which has underlined the importance of diabetes care devices. Pandemic emergency has created a rise in remote care.

Egypt is the ninth country in terms of Diabetes prevalence worldwide. Currently, as per IDF, about 18.4% of the adult population in Egypt has diabetes. More than 11% of the Egyptian population suffers from diagnosed Type-2 diabetes according to Egypt Youth Association for Health Development. 73 million adults (20-79) are living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030.

Egypt had witnessed an alarming increase in the prevalence of diabetes, in recent years, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels. Diabetes poses an emerging healthcare burden across the country.

Owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Scope of the Report

The Egypt Diabetes Care Devices Market is segmented into Monitoring Devices (Self-monitoring Blood Glucose Device, Continuous Glucose Monitoring Device), Management Devices (Insulin Pump, Insulin Syringes, Cartridges in Reusable pens, Disposable Pens, and Jet Injectors). The report offers the value (in USD million) for the above segments.

Monitoring Devices (Value and Volume, 2016-2027)
Self-monitoring Blood Glucose Devices
Glucometer Devices
Blood Glucose Test Strips
Continuous Glucose Monitoring Devices
Durables (Receivers and Transmitters)
Management Devices (Value and Volume, 2016-2027)
Insulin Pump
Insulin Pump Device
Insulin Pump Reservoir
Insulin Pump Monitor
Infusion Set
Insulin Pump Reservoir
Insulin Syringes
Insulin Infusion Sets
Cartridges in Reusable pens
Insulin Disposable Pens
Jet Injectors

Report scope can be customized per your requirements. Click here.

Key Market Trends

Continuous Glucose Monitoring Segment is Expected to Witness Highest Growth Rate Over the Forecast Period

Continuous Glucose Monitoring Segment recorded more than USD 22 million in revenue in 2021, which is expected to further increase with a CAGR of more than 14% during the forecast period.

Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with the platinum inside the sensor, producing an electrical signal to be communicated to the transmitter. Sensors are the most important part of continuous glucose monitoring devices. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period.

The COVID-19 pandemic emphasizes the need for good glycemic control in patients with diabetes, in large part because most observational studies have reported that poorly controlled diabetes is associated with a higher risk for hospitalization and death from a viral illness. The frequency of monitoring glucose levels depends on the type of diabetes, which varies from patient to patient. Type-1 diabetic patients need to check their blood glucose levels at regular intervals, monitor their blood glucose levels, and adjust the insulin dosing accordingly. The current CGM devices show a detailed representation of blood glucose patterns and tendencies compared to a routine check of glucose levels at set intervals. Furthermore, the current continuous glucose monitoring devices can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays.

The use of CGM by Type-1 diabetic patients is very less, as compared to Type-2 diabetic patients. But the expenditure incurred by Type-1 diabetic patients on these devices is nearly double that of Type-2 diabetics. The newest CGM models, the Abbott Freestyle Libre and the Dexcom G6 overcame many technical barriers.

COVID-19 had a detrimental effect on glucose management and caused tension and anxiety among Egyptian Diabetes patients due to COVID-19. Patients were required to minimize their glucose monitoring due to the limited supply and concern over a scarcity of medical supplies. The care of children and adolescents with type 1 diabetes (T1D) in Egypt has been significantly hampered by the coronavirus disease (COVID-19) pandemic. An increase in the frequency of newly diagnosed cases was identified during the first and the second COVID-19 waves compared with the pre-COVID-19 period. The patients presented with more severe Diabetes ketoacidosis, probably due to a more delayed presentation. The frequency of hypokalemia development was also significantly higher, and the severity of Diabetes ketoacidosis was associated with longer ICU admission. Due to this after the coronavirus pandemic also diabetes patients still needed to monitor their glucose levels more than ever before.

The major risk observed among the Egypt population is unhealthy diet, sedentary lifestyle habits, and family history of diabetes. The Egypt blood glucose monitoring market has majorly grown to monitor glycosylated hemoglobin (HbA1c) levels. The major risk observed among the Egypt population is unhealthy diet, sedentary lifestyle habits, and family history of diabetes. Most diabetic patients in Egypt use blood glucose monitoring devices to control blood glucose levels and their fluctuations. Thus, because of the high diabetes population, limited supply during COVID-19 and technological adaptation, the market is growing in Egypt.

Type-1 Diabetes

Insulin Disposable pens Occupied the Highest Share in the Management Devices Segment in 2021

Insulin Disposable pens occupied the highest market share of more than 45% in the management devices segment in 2021.

An insulin disposable pen contains a prefilled amount of insulin, when the pen is empty, it is thrown away. Insulin pens are much smaller and more portable than syringes and have the medicine preloaded into the delivery mechanism. The needles are easy to use and can be disposed of by twisting or snapping after use. The pens are usually color-coded which makes it easier to know which type of insulin and how much insulin will be received from them. The insulin disposable pens are considered more consumer-friendly, as they are smaller and less noticeable than the classic vial-and-syringe. These devices are also more portable for consumers on the go. Some pens are ‘smart insulin pens’ which easily connect to an app on phone to monitor blood sugar levels and remind when to take the next insulin dose.

The increase in the use of disposable pens is also due to the recent pandemic, which has stimulated the growth of telemedical solutions and digital health, to decrease the influx of patients in hospitals and thus stem the spread of the virus.

In Egypt, the social level plays an important role in patients’ access to health care as the number of health care centers, hospitals, and pharmacies is very low in rural areas compared to big cities and urban areas. The financial level is a major determinant of people’s access to health care as the salaries of most of the employees in Egypt are not enough to afford their monthly diabetes supplies. For students and school children with type 1 diabetes, the National Health Insurance System covers insulin, and the student pays nothing for NPH, mixed and short-acting insulins, and only 60% of the price of other types of insulin which are usually not available in the pharmacies of the National Health Insurance System. However, the government is working in the direction of improving the access of patients through various initiatives. The Egyptian Government Launched the “100 million Seha” initiative, which seeks to screen Egyptians for Non-Communicable Diseases (NCDs) like diabetes. Various healthcare companies announced their collaboration with the Egypt Ministry of Health to promote the initiative. Such initiatives are expected to create awareness among the people regarding the monitoring and control of diabetes, thereby enhancing the market prospects in the years to come.

Revenue Share

Competitive Landscape

The diabetes devices market in Egypt includes several established global players like Abbott, LifeScan, F. Hoffmann-La Roche AG, and Novo Nordisk. The CGM market in Egypt comprises only a few players that occupy major shares.

Major Players

  1. Abbott Diabetes Care

  2. Lifescan Inc.

  3. F. Hoffmann-La Roche AG

  4. Novo Nordisk A/S

  5. Medtronic PLC

Egypt diabetes care devices Comp.png

Recent Development

  • In June 2022, Abbott announced that it's developing a new bio-wearable that will continuously monitor glucose and ketone levels in one sensor.
  • In June 2022, Julphar, one of the largest pharmaceutical companies in the Middle East and Africa, attended a business meeting with the Prime Minister of the Arab Republic of Egypt stressing the UAE investments in Egypt in line with the UAE's strategic plan, policy, and external approach.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 Monitoring Devices (Value and Volume, 2016-2027)

      1. 5.1.1 Self-monitoring Blood Glucose Devices

        1. Glucometer Devices

        2. Blood Glucose Test Strips

        3. Lancets

      2. 5.1.2 Continuous Glucose Monitoring Devices

        1. Sensors

        2. Durables (Receivers and Transmitters)

    2. 5.2 Management Devices (Value and Volume, 2016-2027)

      1. 5.2.1 Insulin Pump

        1. Insulin Pump Device

        2. Insulin Pump Reservoir

          1. Insulin Pump Monitor

        3. Infusion Set

          1. Insulin Pump Reservoir

      2. 5.2.2 Insulin Syringes

        1. Insulin Infusion Sets

      3. 5.2.3 Cartridges in Reusable pens

      4. 5.2.4 Insulin Disposable Pens

      5. 5.2.5 Jet Injectors


    1. 6.1 Type-1 Diabetes Population (2016-2027)

    2. 6.2 Type-2 Diabetes Population (2016-2027)



      1. 7.1.1 Dexcom Inc.

      2. 7.1.2 Omnipod

      3. 7.1.3 Medtronic PLC

      4. 7.1.4 F. Hoffmann-La Roche AG

      5. 7.1.5 Novo Nordisk A/S

      6. 7.1.6 Ascensia Diabetes Care

      7. 7.1.7 Agamatrix Inc.

      8. 7.1.8 Bionime Corporation

      9. 7.1.9 Lifescan Inc.

      10. 7.1.10 Abbott Diabetes Care

      11. 7.1.11 Eli Lilly

      12. 7.1.12 Sanofi

      13. 7.1.13 Rossmax


You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Egypt Diabetes Care Devices Market market is studied from 2016 - 2027.

The Egypt Diabetes Care Devices Market is growing at a CAGR of >3.5% over the next 5 years.

The Egypt Diabetes Care Devices Market is valued at 359 Million USD in 2016.

The Egypt Diabetes Care Devices Market is valued at 430 Million USD in 2027.

Abbott Diabetes Care, Lifescan Inc., F. Hoffmann-La Roche AG, Novo Nordisk A/S, Medtronic PLC are the major companies operating in Egypt Diabetes Care Devices Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!